Quest Diagnostics Inc (DGX)

Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease TestingJune 24, 2026 8:52 AM
PR Newswire (US) Achieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack MRD for patients with solid tumor cancersSECAUCUS, N.J., June 24, 2026 /PRNewswire/ -- Quest Diagnostics® (NYSE: DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has approved the company's Haystack MRD® test, a circulating tumor DNA (ctDNA) liquid biopsy test, for use in identifying residual or recurring disease in patients with a range of solid tumor cancers. New York maintains a highly rigorous clinical laboratory oversight program, requiring formal technical review and approval of laboratory developed tests before they may be offered to patients in the state. With this approval, Haystack MRD is now authorized for patient testing in all 50 U.S. states. The test was developed under CLIA regulations and has been available for clinician ordering since late 2024 in 49 states and the District of Columbia."This approval represents the culmination of our many years of hard work and commitment to delivering a highly accurate test that can meaningfully improve patient care," said Dan Edelstein, Vice President and General Manager for Haystack Oncology, a Quest Diagnostics company. "Haystack MRD was designed to give oncologists the confidence to detect residual disease earlier, catch recurrence before it becomes clinically apparent, and help identify response to treatment. New York's approval is another proof point for Haystack MRD's quality and technical sophistication, and we look forward to extending access to this important innovation for clinicians and patients in the state."In addition, Haystack MRD's clinical utility has been demonstrated in rigorous investigational settings, including the landmark study of non-operative management of patients with locally advanced mismatch repair–deficient (dMMR) solid tumors, which was led by Dr. Andrea Cercek and colleagues at Memorial Sloan Kettering Cancer Center and published in The New England Journal of Medicine in May 2025. In that study, ctDNA testing, using Haystack MRD, was found to be a "reliable liquid biopsy surrogate" that identified clinical complete response at a median of 1.4 months, compared to more than 6 months using imaging methods."In our study of non-operative management for dMMR solid tumors, the use of MRD testing provided additional molecular information that complemented traditional assessments such as imaging and endoscopy," said Dr. Cercek, Medical Oncologist, Memorial Sloan Kettering Cancer Center. "For patients who may avoid surgery, having multiple tools to evaluate treatment response and monitor for recurrence is important. These findings highlight the crucial role of MRD testing in informing patient management and underscore the need for continued study as these approaches are integrated into clinical practice."About Haystack Oncology
Haystack Oncology represents the culmination of over 20 years of collaboration to advance technical and clinical development in liquid biopsy technologies by cancer genomics pioneers at Johns Hopkins School of Medicine. The company, a wholly owned subsidiary of Quest Diagnostics, developed Haystack MRD, a tumor-informed, next-generation MRD test that detects ultralow levels of ctDNA to uncover residual or recurrent disease with exceptional sensitivity and specificity. Haystack Oncology works with biopharmaceutical companies to accelerate and inform clinical development programs and advance important therapeutics to global markets, from early phase clinical development to companion diagnostics. Haystack MRD was developed and validated in a CLIA-certified laboratory and is available for commercial use as a lab-developed test (LDT) by Quest Diagnostics. The FDA granted Haystack MRD Breakthrough Device Designation in 2025 for use in Stage II colorectal cancer. Haystack MRD is also available for clinical trials as an investigational device by Haystack Oncology in laboratories located in Baltimore, Maryland; Hamburg, Germany; and Helsinki, Finland. www.haystackmrd.comAbout Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-receives-new-york-state-approval-for-haystack-mrd-broadening-patient-access-to-ctdna-minimal-residual-disease-testing-302808184.htmlSOURCE Quest Diagnostics Original: Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest DiagnosticsJune 18, 2026 8:57 AM
PR Newswire (US) Published in Nature Communications, the new study finds that nearly 70% of a common bacterial strain that causes urinary tract infections, pneumonia and wound infections was non-susceptible to the three most used oral antibioticsSECAUCUS, N.J., June 18, 2026 /PRNewswire/ -- A common bacterial strain that lives naturally in people's guts can cause a dangerous or deadly infection for some, especially when it becomes multidrug-resistant and causes chronic urinary-tract infections (UTIs) in elderly women. But the extent of its effect on the broader population and its prevalence in the community was not well known – until now. Klebsiella pneumoniae is a growing drug-resistance problem, according to a groundbreaking new study in the peer-reviewed Nature Communications by scientists from the Hackensack Meridian Center for Discovery and Innovation (CDI), part of Hackensack Meridian Health (HMH), and Quest Diagnostics (NYSE: DGX), one of the nation's leading providers of diagnostic information services.More than 2,000 samples across 42 states were screened through the collaboration, as outlined in the paper entitled "Nationwide spread of multidrug resistant Klebsiella pneumoniae across U.S. communities." A total of 267 multidrug resistant sequence types were identified, the data finds."For a long time, highly resistant superbugs were primarily considered a problem for hospitals, but this study reveals a dangerous shift. These bacteria are spreading, and causing common infections that are resistant to the recommended antibiotics used to treat them," said co-author Meghan W. Starolis, MS, Ph.D., senior science director, Infectious Disease, Quest Diagnostics. "This research provides critical updates for public health, and, more importantly, it provides the genetic blueprint needed to start developing vaccines or other treatments for vulnerable patients."Klebsiella pneumoniae is an overlooked threat. It not only causes urinary tract infections, pneumonia and wound infections, but also kills about 600,000 individuals annually worldwide, according to the World Health Organization. In the United States, it's the most common cause of hospital-acquired pneumonia. Worldwide, it's the second-leading cause of UTIs – and has shown itself to be especially prevalent in women of advanced age."Our work shows that there is a rapidly-evolving, plasmid-driven epidemic of community-associated multidrug resistant Klebsiella pneumoniae across the United States," said co-author Barry Kreiswirth, Ph.D., the veteran microbiologist at the CDI and professor of Medical Sciences at the Hackensack Meridian School of Medicine, who spearheaded the years-long project. "We need to continue surveillance of what these bacteria are doing, so we can detect, and ideally control, the emergence of the next high-risk clone."Of the roughly 2,000 samples in the study, more than two-thirds were from female patients, and about three-quarters were from people older than 60. All told, 100 percent of the bacteria investigated were classified as multidrug resistant, and 69.5 percent were non-susceptible to the three most common oral antibiotics (fluoroquinolones, Bactrim and nitrofurantoin), "underscoring the urgent need for new oral treatment options." For patients who have these strains, the only option may be injectable antibiotics, said Kreiswirth.The main culprit in this resistance spread is a gene known as CTX-M-15, which is easily swapped between different bacteria on plasmids (stray strands of DNA outside chromosomes). The gene has spread to hundreds of strains, bringing with it not only antibiotic-resistance traits but also tolerance for stress and metal exposure which has potentially enhanced its survival outside of human hosts, according to the findings.The multidrug-resistant strains were previously identified mostly as a healthcare-associated pathogen. Beginning around 2007, however, studies started to identify an "expanding and under-recognized reservoir" of the culprit Extended-Spectrum Beta-Lactamase (ESBL) gene. The U.S. Centers for Disease Control and Prevention conducted a study finding a 53.3 percent increase in ESBL-producing bacteria between 2012 and 2017 – pointing toward community transmission.The study by the CDI and Quest bridges that gap, the authors write. Geographical trends  showed regional and statewide spread, and multi-state dissemination, "indicating widespread, underrecognized community reservoirs," according to the analysis.Quest and CDI worked together to make this research possible. Using its nationwide network of microbiology labs, Quest Diagnostics provided CDI with deidentified culture isolates that were determined to be resistant to antibiotics for further sequencing by CDI, providing the researchers with a diverse sample set for analyzing."This is establishing a baseline," concluded Kreiswirth. "We need to keep looking at this to better understand the extent of the problem. But this is definite confirmation that there is a problem – and it needs to be addressed."The study's strengths include its large scale and unique focus on everyday community infections rather than hospital cases; however, its limitation is the lack of detailed patient medical histories, making it difficult to know exactly where or how the patients originally contracted the infections."We are very proud to collaborate with the Center for Discovery and Innovation on this research," said Yuri Fesko, M.D., senior vice president and chief medical officer, Quest Diagnostics. "Relationships between commercial clinical labs and research organizations like CDI are so important to improving and informing public health."Quest and Hackensack Meridian have a long-standing collaboration through which Quest provides reference laboratory testing and manages HMH's inpatient hospital labs. The study is the largest yet by researchers with the two NJ-based organizations.ABOUT HACKENSACK MERIDIAN HEALTH
Hackensack Meridian Health brings together leading–edge care, research, and medical education to deliver the best outcomes, and care shaped around the unique needs of every patient we serve. By connecting prevention, specialty care, and life-saving discoveries, we improve every aspect of healthcare – from routine visits to the most advanced treatments, close to home and across the globe.Home to New Jersey's first and only top 20 hospital in the nation according to U.S. News & World Report 2025-26, we ensure people can count on exceptional care today and benefit from the cures of tomorrow. Our not-for-profit network of 18 hospitals, 500+ care locations, and over 40,000 team members extend the horizon of health for all. And because medicine is never finished, we Keep Getting Better for every patient, family, and community who counts on us. Learn more at HackensackMeridianHealth.org and to donate visit GiveHMH.org. About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com  View original content to download multimedia:https://www.prnewswire.com/news-releases/uti-causing-bacteria-resistant-to-current-drugs-finds-national-study-by-hackensack-meridian-cdi-and-quest-diagnostics-302803570.htmlSOURCE Quest Diagnostics Original: UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics

Quest Diagnostics Declares Quarterly Cash DividendMay 19, 2026 4:37 PM
PR Newswire (US) SECAUCUS, N.J., May 19, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on July 22, 2026 to shareholders of record of Quest Diagnostics common stock on July 8, 2026. About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com. View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-declares-quarterly-cash-dividend-302776544.htmlSOURCE Quest Diagnostics Original: Quest Diagnostics Declares Quarterly Cash Dividend

Quest Diagnostics Prices $500 Million of Senior NotesApril 27, 2026 4:10 PM
PR Newswire (US)

SECAUCUS, N.J., April 27, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) (the "Company"), a leader in diagnostic information services, today announced the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 (the "Notes") under Quest Diagnostics' shelf registration statement. 







Quest Diagnostics expects to receive the net offering proceeds upon closing on May 6, 2026, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering for general corporate purposes, which may include the repayment of indebtedness. The indebtedness the Company may repay with the net proceeds of this offering includes its $500 million aggregate principal amount of 3.45% Senior Notes which will mature on June 1, 2026.This press release shall not constitute an offer to sell or a solicitation of an offer to purchase any of these securities and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. This offering may be made only by means of a prospectus supplement and accompanying base prospectus, copies of which or information concerning this offering may be obtained by calling Goldman Sachs & Co. LLC, toll free at 1 (866) 471-2526, J.P. Morgan Securities LLC, collect at 1-212-834-4533 or Mizuho Securities USA LLC, toll free at 1-866-271-7403.About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives.Forward Looking Statements 
The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs, including with regard to the consummation of the offering of the Notes, and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the Company include, but are not limited to, uncertain and volatile economic conditions, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government policies, including related to trade, and regulations, changing relationships with customers, payers, suppliers or strategic partners, acquisitions and other factors discussed in the Company's most recently filed Annual Report on Form 10-K and in any of the Company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports. 



View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-prices-500-million-of-senior-notes-302754723.htmlSOURCE Quest Diagnostics

Original: Quest Diagnostics Prices $500 Million of Senior Notes

Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026April 21, 2026 6:47 AM
PR Newswire (US)

First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growthFirst quarter reported diluted earnings per share ("EPS") of $2.24, up 15.5% from 2025; and adjusted diluted EPS of $2.50, up 13.1% from 2025Full year 2026 reported diluted EPS now expected to be between $9.58 and $9.78; and adjusted diluted EPS is expected to be between $10.63 and $10.83SECAUCUS, N.J., April 21, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2026.







"Our more than 9% revenue growth, almost entirely organic, and approximately 13% adjusted diluted earnings per share growth reflect our team's disciplined execution of our strategy to deliver innovative diagnostic solutions for our customers' evolving needs," said Jim Davis, Chairman, CEO and President. "We are raising our revenue and EPS guidance for the year, given our robust first quarter performance and continued strategic focus." Recent Highlights:Serving Clinicians and Health SystemsContinued to advance our Co-Lab Solutions implementation and joint venture laboratory with Corewell Health, a leading health system in Michigan.Scaled our lab and water purity testing solutions for several dialysis clinics and hospitals, extending our reach beyond dialysis clinics owned by Fresenius Medical Care in the United States.Serving ConsumersGrew revenues robustly across the consumer channel through our questhealth.com platform and collaborations with top consumer health companies.Delivering Diagnostic InnovationsGenerated double-digit revenue growth in several areas of Advanced Diagnostics, including for our Quest AD-Detect® blood tests for Alzheimer's disease and in several clinical areas of advanced cardiometabolic and endocrine disease.Formed a research collaboration with City of Hope to study the use of Haystack MRD® as an aid in cancer monitoring and treatment decisions for four solid tumor cancers at 14 U.S. sites.Driving Operational ExcellenceLaunched our AI Companion tool to help patients better understand their lab test reports. Patients have engaged Quest AI Companion approximately 350,000 times since we rolled it out to users of our myQuest patient app earlier this quarter.Advanced our planning and design work for Project Nova, our multi-year initiative to transform our order-to-cash processes and systems, with plans to implement our first wave of solutions in the fall of 2027.
Three Months Ended March 31,
2026
2025
Change
(dollars in millions, except per share data)Reported:




Net revenues$       2,895
$       2,652
9.2 %Diagnostic Information Services revenues$       2,832
$       2,589
9.4 %Revenue per requisition



(1.3) %Requisition volume



10.9 %  Organic requisition volume



10.8 %Operating income (a)$          399
$          346
15.5 %Operating income as a percentage of net revenues (a)                         13.8 %
13.0 %
0.8 %Net income attributable to Quest Diagnostics (a)$          252
$          220
14.4 %Diluted EPS (a)$         2.24
$         1.94
15.5 %Cash provided by operations $          278
$          314
(11.6) %Capital expenditures$          114
$          117
(1.8) %





Adjusted (a):




Operating income$          447
$          406
10.0 %Operating income as a percentage of net revenues15.4 %
15.3 %
0.1 %Net income attributable to Quest Diagnostics$          281
$          251
12.1 %Diluted EPS$         2.50
$         2.21
13.1 %(a) For further details impacting the year-over-year comparisons related to operating income, operating income asa percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of thefinancial tables attached below.Updated Guidance for Full Year 2026The company updates its full year 2026 guidance as follows:
Updated Guidance
Prior Guidance
Low
High
Low
HighNet revenues$11.78 billion
$11.90 billion
$11.70 billion
$11.82 billionNet revenues increase6.8 %
7.8 %
6.0 %
7.1 %Reported diluted EPS$9.58
$9.78
$9.45
$9.65Adjusted diluted EPS$10.63
$10.83
$10.50
$10.70Cash provided by operationsApproximately $1.75 billion
Approximately $1.75 billionCapital expenditures  Approximately $550 million
Approximately $550 millionNote on Non-GAAP Financial MeasuresAs used in this press release the term "reported" refers to measures under accounting principles generally accepted in the United States ("GAAP"). The term "adjusted" refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, gains and losses associated with changes in the carrying value of our strategic investments and other items.Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures.Conference Call Information Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today.  The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: 7895081; or via live webcast on our website at www.QuestDiagnostics.com/investor.  We suggest participants dial in approximately 10 minutes before the call.A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or, from approximately 10:30 a.m. Eastern Time on April 21, 2026 until midnight Eastern Time on May 5, 2026, by phone at 866-388-5361 for domestic callers or 203-369-0416 for international callers.  Anyone listening to the call is encouraged to read our periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.About Quest DiagnosticsQuest Diagnostics works across healthcare to create a healthier world, one life at a time. We help connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, our insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three adult Americans each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com.Forward Looking StatementsThe statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, uncertain and volatile economic conditions, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government policies, including related to trade, and regulations, changing relationships with customers, payers, suppliers or strategic partners, acquisitions and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.For further information: Wendy Bost, Quest Diagnostics (Media): 973-520-2800, Daniel Haemmerle, Quest Diagnostics (Investors): 973-520-2900This earnings release, including the attached financial tables, is available online in the Newsroom section at www.QuestDiagnostics.com.  Quest Diagnostics Incorporated and SubsidiariesConsolidated Statements of OperationsFor the Three Months Ended March 31, 2026 and 2025 (in millions, except per share data)(unaudited)

Three Months Ended
March 31,
2026
2025Net revenues $    2,895
$    2,652



Operating costs and expenses and other operating income:


Cost of services1,953
1,789Selling, general and administrative 504
476Amortization of intangible assets37
39Other operating expense, net2
2Total operating costs and expenses, net 2,496
2,306



Operating income399
346



Other income (expense):


Interest expense, net(63)
(67)Other expense, net(2)
(3)Total non-operating expense, net(65)
(70)



Income before income taxes and equity in earnings of equity method investees334
276Income tax expense(74)
(59)Equity in earnings of equity method investees, net of taxes4
18Net income264
235Less: Net income attributable to noncontrolling interests12
15Net income attributable to Quest Diagnostics$       252
$       220



Earnings per share attributable to Quest Diagnostics' common stockholders:


Basic$      2.27
$      1.97



Diluted$      2.24
$      1.94



Weighted average common shares outstanding:


Basic110
111



Diluted112
113 Quest Diagnostics Incorporated and SubsidiariesConsolidated Balance SheetsMarch 31, 2026 and December 31, 2025 (in millions, except per share data)(unaudited)

March 31,
2026
December 31,
2025Assets


Current assets:


Cash and cash equivalents$                 393
$                420Accounts receivable, net1,587
1,408Inventories225
189Prepaid expenses and other current assets361
361Total current assets2,566
2,378Property, plant and equipment, net2,189
2,203Operating lease right-of-use assets691
657Goodwill9,120
8,945Intangible assets, net1,717
1,636Investments in equity method investees134
136Other assets256
270Total assets$            16,673
$           16,225



Liabilities and Stockholders' Equity


Current liabilities:


Accounts payable and accrued expenses$              1,500
$             1,600Current portion of long-term debt503
504Current portion of long-term operating lease liabilities174
174Total current liabilities2,177
2,278Long-term debt5,155
5,167Long-term operating lease liabilities574
537Other liabilities1,022
957Redeemable noncontrolling interest79
80Stockholders' equity:


Quest Diagnostics stockholders' equity:


 Common stock, par value $0.01 per share; 600 shares authorized as of both March 31, 2026 and   December 31, 2025; 162 shares issued as of both March 31, 2026 and December 31, 20252
2Additional paid-in capital2,347
2,381Retained earnings10,151
9,994Accumulated other comprehensive loss(43)
(27)Treasury stock, at cost; 51 shares and 52 shares as of March 31, 2026 and December 31, 2025,   respectively(5,091)
(5,180)Total Quest Diagnostics stockholders' equity7,366
7,170Noncontrolling interests300
36Total stockholders' equity7,666
7,206Total liabilities and stockholders' equity$            16,673
$           16,225 Quest Diagnostics Incorporated and SubsidiariesConsolidated Statements of Cash FlowsFor the Three Months Ended March 31, 2026 and 2025 (in millions)(unaudited)

Three Months Ended
March 31,
2026
2025Cash flows from operating activities:


Net income$              264
$              235Adjustments to reconcile net income to net cash provided by operating activities:


Depreciation and amortization147
140Provision for credit losses1
1Deferred income tax expense48
7Stock-based compensation expense20
22Other, net8
(1)Changes in operating assets and liabilities:


Accounts receivable(180)
(101)Accounts payable and accrued expenses(12)
(53)Income taxes payable13
15Other assets and liabilities, net(31)
49Net cash provided by operating activities278
314



Cash flows from investing activities:


Business acquisitions, net of cash acquired(38)
—Capital expenditures(114)
(117)Other investing activities, net—
2Net cash used in investing activities(152)
(115)



Cash flows from financing activities:


Proceeds from borrowings—
215Repayments of debt(1)
(600)Exercise of stock options65
29Employee payroll tax withholdings on stock issued under stock-based compensation plans               (37)
(42)Dividends paid(88)
(84)Distributions to noncontrolling interest partners(7)
(18)Other financing activities, net(84)
(61)Net cash used in financing activities(152)
(561)



Effect of exchange rate changes on cash and cash equivalents and restricted cash(1)
1



Net change in cash and cash equivalents and restricted cash(27)
(361)Cash and cash equivalents and restricted cash, beginning of period420
549Cash and cash equivalents and restricted cash, end of period$              393
$              188



Cash paid during the period for:


Interest$                22
$                32Income taxes$                  8
$                  4Notes to Financial Tables1)  The computation of basic and diluted earnings per common share is as follows:

Three Months Ended
March 31,
2026
2025
(in millions, except per share data)Amounts attributable to Quest Diagnostics' common stockholders:


Net income attributable to Quest Diagnostics$           252
$           220Less: earnings allocated to participating securities1
1Earnings available to Quest Diagnostics' common stockholders - basic and diluted$           251
$           219



Weighted average common shares outstanding - basic110
111Effect of dilutive securities:


Stock options and performance share units2
2Weighted average common shares outstanding - diluted112
113



Earnings per share attributable to Quest Diagnostics' common stockholders:                         


Basic$          2.27
$          1.97Diluted$          2.24
$          1.94 2)  The following tables reconcile reported GAAP results to non-GAAP adjusted results:

Three Months Ended March 31, 2026
(dollars in millions, except per share data)
Operating income
Operating income as a percentage of net revenues
Income tax expense (e)
Equity in earnings of equity method investees, net of taxes
Net income attributable to Quest Diagnostics
Diluted EPSAs reported$                 399
13.8 %
$                  (74)
$                     4
$                 252
$                2.24Restructuring and integration charges (a)7
0.2
(2)
—
5
0.04Other charges (b)4
0.1
(1)
—
3
0.03Gains and losses on investments (c)—
—
(2)
7
5
0.05Amortization expense37
1.3
(9)
—
28
0.25ETB—
—
(12)
—
(12)
(0.11)As adjusted$                 447
15.4 %
$                (100)
$                   11
$                 281
$                2.50




Three Months Ended March 31, 2025
(dollars in millions, except per share data)
Operating income
Operating income as a percentage of net revenues
Income tax expense (e)
Equity in earnings of equity method investees, net of taxes
Net income attributable to Quest Diagnostics
Diluted EPS                                   As reported$                 346
13.0 %
$                  (59)
$                   18
$                 220
$                1.94Restructuring and integration charges (a)19
0.7
(5)
—
14
0.13Other charges (b)2
0.1
—
—
2
0.02Other gains (d)—
—
2
(8)
(6)
(0.06)Amortization expense39
1.5
(9)
—
30
0.26ETB—
—
(9)
—
(9)
(0.08)As adjusted$                 406
15.3 %
$                  (80)
$                   10
$                 251
$                2.21
(a)  For both the three months ended March 31, 2026 and 2025, the pre-tax impact represents costs primarily associated with workforce reductions and integration      costs incurred in connection with further restructuring and integrating our business. The following table summarizes the pre-tax impact of restructuring and      integration charges on our consolidated statements of operations:
Three Months Ended
March 31,
2026
2025
(dollars in millions)Cost of services$               1
$               6Selling, general and administrative                                                                                                                                                   6
13Operating income$               7
$             19

     (b) For both the three months ended March 31, 2026 and 2025, the pre-tax impact primarily represents a loss associated with the change in the fair value of the contingent consideration accrual associated with previous acquisitions, recorded in other operating expense, net.

     (c) For the three months ended March 31, 2026, the pre-tax impact represents losses associated with changes in the carrying value of our strategic investments, principally recorded in equity in earnings of equity method investees, net of taxes.

     (d) The three months ended March 31, 2025 includes pre-tax gains of $8 million, recorded in equity in earnings of equity method investees, net of taxes, principally consisting of a non-recurring gain related to a lease.

     (e) For restructuring and integration charges, other gains/charges, gains and losses on investments, and amortization expense, income tax impacts, where recorded, were primarily calculated using combined statutory income tax rates of 25.5% for both 2026 and 2025.  No income tax impact was recorded on losses associated with the change in the fair value of the contingent consideration accrual associated with previous acquisitions.
3)  The outlook for adjusted diluted EPS represents management's estimates for the full year 2026 before the impact of special items. Further      impacts to earnings related to special items may occur throughout 2026. Additionally, the amount of ETB is dependent upon employee stock      option exercises and our stock price, which are difficult to predict. The following table reconciles our 2026 outlook for diluted EPS under GAAP     to our outlook for adjusted diluted EPS:

Low
HighDiluted EPS$                                   9.58
$                                   9.78Restructuring and integration charges (a)0.10
0.10Amortization expense (b)0.99
0.99Other charges (c)0.10
0.10Gains and losses on investments (d)0.05
0.05ETB(0.19)
(0.19)Adjusted diluted EPS$                                 10.63
$                                 10.83

(a) Represents estimated pre-tax charges of $16 million primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business. Income tax benefits were primarily calculated using a combined statutory income tax rate of 25.5%.

(b) Represents estimated pre-tax amortization expenses of $149 million. Income tax benefits were primarily calculated using a combined statutory income tax rate of 25.5%.

(c) Principally represents estimated pre-tax net losses of $10 million associated with the increase in the fair value of the contingent consideration accrual associated with previous acquisitions. Such estimate is subject to the risks and uncertainties discussed in the "Forward Looking Statements" section above. No income tax benefits are recorded on the changes associated with the contingent consideration accrual.

(d) Income tax impacts were calculated using a combined statutory income tax rate of 25.5%. 



View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-reports-first-quarter-2026-financial-results-raises-revenue-and-eps-guidance-for-full-year-2026-302747831.htmlSOURCE Quest Diagnostics

Original: Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

Quest Diagnostics to Release First Quarter Financial Results on April 21, 2026March 19, 2026 10:00 AM
PR Newswire (US)

SECAUCUS, N.J., March 19, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report first quarter 2026 financial results on Tuesday, April 21, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.







The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.QuestDiagnostics.com/investor. The company suggests participants dial in approximately 10 minutes before the call.A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 866-388-5361 for domestic callers or 203-369-0416 for international callers; no passcode is required. Telephone replays will be available from approximately 10:30 a.m. Eastern Time on April 21, 2026, until midnight Eastern Time on May 5, 2026.Anyone listening to the call is encouraged to read the company's periodic reports on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors, and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com



View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-to-release-first-quarter-financial-results-on-april-21-2026-302717761.htmlSOURCE Quest Diagnostics

Original: Quest Diagnostics to Release First Quarter Financial Results on April 21, 2026

Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of DirectorsMarch 12, 2026 4:07 PM
PR Newswire (US)

SECAUCUS, N.J., March 12, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced that its board of directors has elected Timothy (Tim) Wentworth, a highly seasoned business leader, to serve as a director. Including Mr. Wentworth, the company's board has eleven members.







"As a former CEO of several large, publicly traded healthcare organizations, Tim brings incredible leadership experience to the Quest board," said Jim Davis, chairman, CEO and president of Quest Diagnostics. "His depth in the many channels Quest serves, including health plan, employer and consumer, combined with his real-world operations and HR expertise, makes him an exceptional addition to the Quest team as we work together to create a healthier world, one life at a time."Mr. Wentworth, 65, was most recently chief executive officer (CEO) of Walgreens Boots Alliance, where he helped restructure the company for its sale to Sycamore Partners in mid-2025. Prior to that, he was founding CEO of Evernorth Health Services, the health services organization of The Cigna Group that partners with health plans, employers and government organizations to deliver pharmacy, care, and benefit solutions.In addition, Mr. Wentworth was president and CEO of Express Scripts, one of the largest pharmacy benefit managers in the United States, following the company's 2012 acquisition of Medco Health Solutions, where he held roles as group president, employer accounts and president and CEO of Medco's Accredo Health specialty pharmacy business. With the Medco transaction, Express Scripts grew into a Fortune 25 company with more than $100 billion in revenues before its acquisition by Cigna in 2018.Mr. Wentworth's experience also includes senior leadership roles with top consumer brands, including chief operating officer at Mary Kay, Inc., and director roles in human resources at PepsiCo, Inc.Timothy M. Ring, lead independent director, added: "Tim is an accomplished business leader who knows how to run highly complex, industry-leading healthcare companies to generate growth and value at scale. We are fortunate to welcome him to our board."Mr. Wentworth serves on the boards of directors of Walgreens Holding Company and Dfinitiv, and previously served on the boards of Walgreens Boots Alliance, Accredo Health Group, Express Scripts, and Forge Health. He earned his bachelor's degree in industrial and labor relations from Cornell University and an associate in applied science degree in business administration from Monroe Community College. About Quest DiagnosticsQuest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com










View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-elects-timothy-wentworth-former-ceo-of-walgreens-boots-alliance-evernorth-health-services-and-express-scripts-to-board-of-directors-302712761.htmlSOURCE Quest Diagnostics

Original: Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors

Quest Diagnostics Introduces AI Companion to Help Patients Understand and Act on Lab Test ResultsMarch 2, 2026 9:02 AM
PR Newswire (US)

New feature based on Google's Gemini seamlessly analyzes up to five years of personal lab data to help explain results and uncover potential health risksSECAUCUS, N.J., March 2, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced Quest AI Companion, a new AI-powered chat feature that helps individuals analyze, understand and act on their Quest laboratory test results with their healthcare provider. 







Available now to all adult users of the company's secure, free patient mobile app and portal MyQuest, individuals can engage Quest AI Companion with questions about their test results and immediately receive personalized, easy-to-understand explanations, without leaving the integrated, HIPAA-compliant, MyQuest solution."Patients often tell us they want help simplifying and understanding their test results and what the results communicate about their health," said Nicole Antonson, vice president of digital solutions and interoperability, Quest Diagnostics. "For more than 50 years, Quest has been a trusted provider of laboratory results. Now, Quest AI Companion builds on this history and empowers patients to analyze their results and spot trends they can discuss with their healthcare provider, for smarter and simpler testing that illuminates a path to better health."The new tool is unique because it seamlessly accesses and analyzes up to five years of an individual's lab data from Quest results reports to identify trends and patterns that may indicate health risks. As the Quest AI Companion operates within the secure MyQuest platform, individuals do not need to manually input their laboratory results into a public AI tool, avoiding concerns that may arise when sharing private health data with publicly accessible AI technologies. In addition, users can prompt the tool to define test names and medical terminology from their results reports, as well as translate the meaning of lab values, such as high, low, or within a reference range. Users can also prompt the AI Companion to assist with composing questions they can ask their healthcare provider, empowering patients to have more informed conversations with clinicians.While the use of AI technologies is growing across the healthcare industry, recent reports suggest most individuals do not access Gen AI apps to analyze their personal health data. In a survey conducted by Quest about the use of AI, participants cited privacy and data security, alongside accuracy and reliability, as concerns about the use of AI."People want to understand their lab data, but not everyone feels comfortable uploading their health data to public AI platforms. Quest AI Companion empowers people to access the benefits of gen AI from a healthcare services provider they already know and trust to manage their most personal lab information," said Yuri Fesko, M.D., senior vice president and chief medical officer, Quest Diagnostics.Powered by Google's Gemini family of models, Quest AI Companion is the result of a strategic collaboration with Google Cloud, established in March 2025. Through this relationship, Quest integrates Google Cloud's advanced AI technologies to streamline data management and improve customer experiences. The parties plan to continue to work together to aid patients and providers through innovation.Individuals interested in Quest AI Companion can now access the service through their MyQuest account. Through MyQuest, patients can also schedule appointments, access test results and pay bills. For more information, visit MyQuest.QuestDiagnostics.com.Quest AI Companion is a chat feature intended for individuals to analyze and understand their Quest laboratory test results with their healthcare provider. Users must be at least age 18. Quest AI Companion is not a substitute for professional medical advice or visits to a healthcare provider. Patients should continue to consult with a healthcare provider about test results and any symptoms they may be experiencing. The Quest AI Companion is for educational purposes only and not for use in the diagnosis of disease or other conditions. The information provided by this system should not be used to start, stop, or change any course of treatment unless advised by your healthcare provider.About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com 



View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-introduces-ai-companion-to-help-patients-understand-and-act-on-lab-test-results-302700483.htmlSOURCE Quest Diagnostics

Original: Quest Diagnostics Introduces AI Companion to Help Patients Understand and Act on Lab Test Results

Quest Diagnostics Names Benjamin Beauvalot Senior Vice President, Chief Strategy and M&A OfficerFebruary 26, 2026 8:24 AM
PR Newswire (US)

Veteran M&A and transformation leader from Danaher and Patheon joins the Quest Diagnostics executive teamSECAUCUS, N.J., Feb. 26, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that Benjamin Beauvalot, a highly accomplished leader with more than two decades of experience in business strategy and transformation, including mergers and acquisitions (M&A), has joined the company as senior vice president, chief strategy and M&A officer.







In this role, Mr. Beauvalot is responsible for developing the company's growth strategy and leading mergers and acquisitions, strategic partnerships, and integrations. He reports to Jim Davis, chairman, CEO and president, and is a member of the company's executive leadership team. "Ben has an extensive track record of delivering successful growth, M&A and transformation strategies for world-class healthcare organizations," Mr. Davis said. "His strategic leadership and rigorous approach to business integration will advance Quest's opportunities to generate organic and acquisitive growth, thereby supporting our purpose to create a healthier world, one life at a time."Prior to joining Quest, Mr. Beauvalot held leadership positions in strategy and M&A with Danaher Corporation, a leading global life sciences and diagnostics innovator. Mr. Beauvalot's roles included vice president and head of business development and strategy for Danaher's biotechnology and genomics business areas. Mr. Beauvalot also served as vice president of strategy and corporate development and vice president of global business operations for Patheon, a leading pharmaceutical services company, before its acquisition by Thermo Fisher Scientific in 2017. He was also vice president of strategy for Banner Life Sciences, a specialty pharmaceutical company.Mr. Beauvalot holds a degree in management and business administration from the Institut de Préparation à l'Administration et à la Gestion (IPAG) in Paris, France.Mr. Beauvalot succeeds Dermot Shorten, who is retiring in the second quarter of 2026 after having held the role since 2008. During his time at Quest, Mr. Shorten oversaw nearly 80 business combinations and collaborations, including approximately 20 acquisitions of hospital outreach laboratories over the past decade."On behalf of the entire executive team and all of my Quest colleagues, I am grateful to Dermot for his leadership and contributions, many of which were strategically critical to creating the strong, dynamic business Quest is today," Mr. Davis said. "He played a vital role stewarding our company's successes over the past 18 years and is leaving us with a solid foundation for creating further growth and value."About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.










View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-names-benjamin-beauvalot-senior-vice-president-chief-strategy-and-ma-officer-302698430.htmlSOURCE Quest Diagnostics

Original: Quest Diagnostics Names Benjamin Beauvalot Senior Vice President, Chief Strategy and M&A Officer

Quest Diagnostics posts Q4 beat and upbeat outlook, lifting sharesFebruary 10, 2026 10:13 AM
IH Market News
Quest Diagnostics (NYSE:DGX) delivered fourth-quarter results that topped market expectations on Tuesday, supported by solid operational performance and forward revenue guidance that exceeded analysts’ forecasts.Shares of the diagnostic testing company climbed 2.33% in premarket trading following the announcement.Adjusted earnings came in at $2.42 per share, ahead of the $2.36 expected by analysts, while revenue reached $2.81 billion, surpassing the consensus estimate of $2.75 billion. Fourth-quarter revenue increased 7.1% year on year, driven by an 8.5% rise in requisition volumes, although revenue per requisition edged down slightly by 0.1%.“We closed 2025 with a strong fourth quarter, and delivered double-digit growth in revenues and earnings per share for the full year,” said Jim Davis, Chairman, CEO, and President. “Our robust performance demonstrates continued execution of our strategy to deliver category-defining clinical innovations that fulfill customers’ needs.”Looking ahead, Quest Diagnostics forecast fiscal 2026 revenue of between $11.70 billion and $11.82 billion, well above the analyst consensus of $11.36 billion. The company’s adjusted EPS outlook of $10.50 to $10.70, however, came in slightly below the consensus estimate of $10.42.For full-year 2025, Quest reported revenue of $11.04 billion, up 11.8% from the prior year, while adjusted earnings per share rose 10.3% to $9.85. Operating cash flow for the year totaled $1.89 billion.Quest also highlighted key strategic progress in 2025, including rolling out its largest-ever Co-Lab Solutions deployment for Corewell Health, expanding services across Fresenius Medical Care’s dialysis centers, and integrating eight acquisitions completed in 2024 that extended its geographic footprint, including into Canada.In addition, the company continued to build out its consumer-facing initiatives, expanding its questhealth.com platform to offer more than 150 tests and forming partnerships with leading consumer wellness and wearable technology companies.Quest Diagnostics stock price

Original: Quest Diagnostics posts Q4 beat and upbeat outlook, lifting shares

Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per ShareFebruary 10, 2026 6:47 AM
PR Newswire (US)

Fourth quarter revenues of $2.81 billion, up 7.1% from 2024Fourth quarter reported diluted earnings per share ("EPS") of $2.18, up 11.8% from 2024; and adjusted diluted EPS of $2.42, up 8.5% from 2024Full year revenues of $11.04 billion, up 11.8% from 2024Full year reported diluted EPS of $8.75, up 13.8% from 2024; and adjusted diluted EPS of $9.85, up 10.3% from 2024   Full year cash from operations of $1.89 billionFull year 2026 revenues expected to be between $11.70 billion and $11.82 billion Full year 2026 reported diluted EPS expected to be between $9.45 and $9.65; and adjusted diluted EPS expected to be between $10.50 and $10.70SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2025.







"We closed 2025 with a strong fourth quarter, and delivered double-digit growth in revenues and earnings per share for the full year," said Jim Davis, Chairman, CEO, and President. "Our robust performance demonstrates continued execution of our strategy to deliver category-defining clinical innovations that fulfill customers' needs and to form strategic collaborations supporting growth. Our 2026 guidance reflects our continued confidence in our business strengths and market fundamentals."Key 2025 Highlights:Serving Clinicians and Health SystemsBegan to deploy our largest Co-Lab Solutions implementation to date for Corewell Health, a leading health system in Michigan. Also finalized a laboratory-services joint venture with Corewell Health that includes plans to open a state-of-the-art laboratory in southeast Michigan in 2027.Scaled lab testing to deliver services for more than 200,000 patients at Fresenius Medical Care's dialysis centers in the United States while also adding leading water-purity testing capabilities to our menu.Integrated eight acquisitions completed in 2024, providing the basis for growth in new geographies, including Canada.Expanded and initiated new collaborations to serve in-network providers and members in new geographies.Formed a first-of-its-kind collaboration with Epic to be our technology partner for Project Nova, our multi-year order-to-cash transformation to streamline systems and improve customer experiences, regardless of the electronic health record they use, for smarter, simpler testing.Serving ConsumersFurther advanced our position as the premier lab engine powering the wellness industry through questhealth.com, our consumer-initiated test platform, and through new collaborations with top consumer wellness and wearables companies.Expanded our offerings on questhealth.com to more than 150 tests, including our new Elite Health Panel for assessing health based on over 85 biomarkers.Delivering Clinical InnovationsAdded category-defining innovations to our Advanced Diagnostics portfolio, including a new Quest AD-Detect® blood test for aiding the diagnosis of Alzheimer's disease, long-read gene sequencing to identify the cause of ataxia movement disorders, and HPV self-collection options for cervical cancer screening. Secured FDA breakthrough device designation for the Haystack MRD® test for monitoring patients treated for solid-tumor cancers.Formed collaborations with The University of Texas MD Anderson Cancer Center and Rutgers Cancer Institute to research and develop innovations for detecting early signs of cancer.Supported public health with Oropouche virus testing under a preparedness contract with the U.S. Centers for Disease Control and Prevention.Driving Operational ExcellenceDelivered 3% annual cost savings and productivity improvements through our Invigorate program.Deployed AI and automation across lab, customer and administrative systems, including automated sample processing, logistics and cytology, improving quality, experiences and productivity.Engaged Google Cloud to use generative AI to simplify and improve data management and analytics.  
Three Months Ended December 31,
Twelve Months Ended December 31,
2025
2024
Change
2025
2024
Change
(dollars in millions, except per share data)Reported:










Net revenues$   2,806
$   2,621
7.1 %
$ 11,035
$   9,872
11.8 %Diagnostic information services revenues$   2,742
$   2,556
7.3 %
$ 10,785
$   9,614
12.2 %  Revenue per requisition



(0.1) %




0.1 %  Requisition volume



8.5 %




12.3 %  Organic requisition volume



7.9 %




3.4 %Operating income (a)$      386
$      361
7.0 %
$   1,556
$   1,346
15.6 %Operating income as a percentage of net revenues
     (a)13.8 %
13.8 %
— %
14.1 %
13.6 %
0.5 %Net income attributable to Quest Diagnostics (a)$      245
$      222
10.7 %
$      992
$      871
13.9 %Diluted EPS (a)$     2.18
$     1.95
11.8 %
$     8.75
$     7.69
13.8 %Cash provided by operations$      465
$      464
0.5 %
$   1,886
$   1,334
41.4 %Capital expenditures$      158
$      123
27.4 %
$      527
$      425
23.8 %











Adjusted (a):










Operating income$      429
$      409
4.7 %
$   1,759
$   1,541
14.1 %Operating income as a percentage of net revenues15.3 %
15.6 %
(0.3) %
15.9 %
15.6 %
0.3 %Net income attributable to Quest Diagnostics$      273
$      253
7.4 %
$   1,118
$   1,011
10.5 %Diluted EPS                      $     2.42
$     2.23
8.5 %
$     9.85
$     8.93
10.3 %a)For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below.Guidance for Full Year 2026The company estimates its full year 2026 guidance in the table below. The company has included a presentation that includes additional guidance information on the Events and Presentations page of its investor relations website, which can be found at www.QuestDiagnostics.com/investor.
Low
HighNet revenues$11.70 billion
$11.82 billionNet revenues increase6.0 %
7.1 %Reported diluted EPS$9.45
$9.65Adjusted diluted EPS$10.50
$10.70Cash provided by operationsApproximately $1.75 billionCapital expendituresApproximately $550 millionNote on Non-GAAP Financial MeasuresAs used in this press release the term "reported" refers to measures under accounting principles generally accepted in the United States ("GAAP"). The term "adjusted" refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, gains and losses associated with changes in the carrying value of our strategic investments, impairment charges and other items.Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures.Conference Call InformationQuest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today.  The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: 7895081; or via live webcast on our website at www.QuestDiagnostics.com/investor.  We suggest participants dial in approximately 10 minutes before the call.A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or, from approximately 10:30 a.m. Eastern Time on February 10, 2026 until midnight Eastern Time on February 24, 2026, by phone at 866-388-5361 for domestic callers and 203-369-0416 for international callers. Anyone listening to the call is encouraged to read our periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.About Quest DiagnosticsQuest Diagnostics works across healthcare to create a healthier world, one life at a time. We help connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, our insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three adult Americans each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.comForward Looking StatementsThe statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, uncertain and volatile economic conditions, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government policies, including related to trade, and regulations, changing relationships with customers, payers, suppliers or strategic partners, acquisitions and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.This earnings release, including the attached financial tables, is available online in the Newsroom section at www.QuestDiagnostics.com.ADDITIONAL TABLES FOLLOW Quest Diagnostics Incorporated and Subsidiaries
Consolidated Statements of Operations 
For the Three and Twelve Months Ended December 31, 2025 and 2024 
(in millions, except per share data)
(unaudited)  
Three Months Ended December 31,
Twelve Months Ended December 31,
2025
2024
2025
2024Net revenues$    2,806
$    2,621
$  11,035
$    9,872







Operating costs and expenses and other operating income:






Cost of services1,896
1,763
7,370
6,628Selling, general and administrative504
466
1,967
1,770Amortization of intangible assets37
37
154
127Other operating (income) expense, net(17)
(6)
(12)
1Total operating costs and expenses, net2,420
2,260
9,479
8,526







Operating income386
361
1,556
1,346







Other income (expense):






Interest expense, net(64)
(65)
(264)
(201)Other income, net8
3
26
30Total non-operating expense, net(56)
(62)
(238)
(171)







Income before income taxes and equity in earnings of
     equity method investees330
299
1,318
1,175Income tax expense(81)
(68)
(314)
(273)Equity in earnings of equity method investees, net of taxes7
5
42
19Net income256
236
1,046
921Less: Net income attributable to noncontrolling interests11
14
54
50Net income attributable to Quest Diagnostics$       245
$       222
$       992
$       871







Earnings per share attributable to Quest Diagnostics' common
    stockholders:






Basic$      2.21
$      1.98
$      8.87
$      7.78







Diluted$      2.18
$      1.95
$      8.75
$      7.69







Weighted average common shares outstanding:






Basic111
111
111
111







Diluted112
113
113
113







 Quest Diagnostics Incorporated and SubsidiariesConsolidated Balance SheetsDecember 31, 2025 and 2024 (in millions, except per share data)(unaudited)
December 31,
2025
December 31,
2024Assets


Current assets:


Cash and cash equivalents$                 420
$                549Accounts receivable, net1,408
1,304Inventories189
188Prepaid expenses and other current assets361
351Total current assets2,378
2,392Property, plant and equipment, net2,203
2,113Operating lease right-of-use assets657
651Goodwill8,945
8,856Intangible assets, net1,636
1,763Investment in equity method investees136
123Other assets270
255Total assets$            16,225
$           16,153



Liabilities and Stockholders' Equity


Current liabilities:


Accounts payable and accrued expenses$              1,600
$             1,394Current portion of long-term debt504
602Current portion of long-term operating lease liabilities174
173Total current liabilities2,278
2,169Long-term debt5,167
5,615Long-term operating lease liabilities537
535Other liabilities957
938Redeemable noncontrolling interest80
83Stockholders' equity:


Quest Diagnostics stockholders' equity:


Common stock, par value $0.01 per share; 600 shares authorized as of both December 31, 2025
  and 2024; 162 shares issued as of both December 31, 2025 and 20242
2Additional paid-in capital2,381
2,361Retained earnings9,994
9,360Accumulated other comprehensive loss(27)
(88)Treasury stock, at cost; 52 shares and 51 shares as of December 31, 2025 and 2024, respectively(5,180)
(4,857)Total Quest Diagnostics stockholders' equity7,170
6,778Noncontrolling interests36
35Total stockholders' equity7,206
6,813Total liabilities and stockholders' equity$            16,225
$           16,153  Quest Diagnostics Incorporated and SubsidiariesConsolidated Statements of Cash FlowsFor the Twelve Months Ended December 31, 2025 and 2024 (in millions)(unaudited)
Twelve Months Ended
December 31,
2025
2024Cash flows from operating activities:


Net income$        1,046
$           921Adjustments to reconcile net income to net cash provided by operating activities:


Depreciation and amortization570
493Provision for credit losses3
5Deferred income tax provision105
13Stock-based compensation expense88
88Other, net24
15Changes in operating assets and liabilities:


Accounts receivable(106)
(71)Accounts payable and accrued expenses129
(67)Income taxes payable24
16Other assets and liabilities, net3
(79)Net cash provided by operating activities1,886
1,334



Cash flows from investing activities:


Business acquisitions, net of cash acquired(101)
(2,164)Capital expenditures(527)
(425)Other investing activities, net(3)
41Net cash used in investing activities(631)
(2,548)



Cash flows from financing activities:


Proceeds from borrowings410
1,846Repayments of debt(1,012)
(303)Purchases of treasury stock(450)
(151)Exercise of stock options79
73Employee payroll tax withholdings on stock issued under stock-based compensation plans(45)
(24)Dividends paid(353)
(331)Distributions to noncontrolling interest partners(56)
(47)Other financing activities, net39
21Net cash (used in) provided by financing activities(1,388)
1,084



Effect of exchange rate changes on cash and cash equivalents and restricted cash4
(7)



Net change in cash and cash equivalents and restricted cash(129)
(137)Cash and cash equivalents and restricted cash, beginning of period549
686Cash and cash equivalents and restricted cash, end of period$           420
$           549



Cash paid during the period for:


Interest$           280
$           262Income taxes$           169
$           256 Notes to Financial Tables1)  The computation of basic and diluted earnings per common share is as follows:

Three Months Ended December 31,
Twelve Months Ended December 31,
2025
2024
2025
2024
(in millions, except per share data)Amounts attributable to Quest Diagnostics' common stockholders:






Net income attributable to Quest Diagnostics$           245
$           222
$           992
$           871Less: Earnings allocated to participating securities—
2
4
5Earnings available to Quest Diagnostics' common stockholders - basic and      diluted$           245
$           220
$           988
$           866







Weighted average common shares outstanding - basic111
111
111
111Effect of dilutive securities:






Stock options and performance share units1
2
2
2Weighted average common shares outstanding - diluted112
113
113
113







Earnings per share attributable to Quest Diagnostics' common      stockholders:






Basic$          2.21
$          1.98
$          8.87
$          7.78Diluted$          2.18
$          1.95
$          8.75
$          7.69 2)  The following tables reconcile reported GAAP results to non-GAAP adjusted results:

Three Months Ended December 31, 2025
(dollars in millions, except per share data)
Operating income
Operating income as a percentage of net revenues
Income tax expense (f)
Equity in earnings of equity methodinvestees, net of taxes
Net income  attributable
to Quest Diagnostics
Diluted EPSAs reported$                 386
13.8 %
$                 (81)
$                     7
$                 245
$                2.18Restructuring and integration charges (a) 16
0.6
1
—
17
0.15Change in fair value of contingent consideration (b)(18)
(0.7)
—
—
(18)
(0.16)Other charges (c)8
0.3
(1)
—
6
0.05Gains and losses on investments (d)—
—
—
3
(2)
(0.02)Amortization expense37
1.3
(9)
—
28
0.25ETB—
—
(3)
—
(3)
(0.03)As adjusted$                 429
15.3 %
$                 (93)
$                   10
$                 273
$                2.42 
Twelve Months Ended December 31, 2025
(dollars in millions, except per share data)
Operating income
Operating income as a percentage of net revenues
Income tax expense (f)
Equity in earnings of equity method investees, net of taxes
Net income  attributable to Quest Diagnostics
Diluted EPSAs reported$             1,556
14.1 %
$               (314)
$                   42
$                 992
$                8.75Restructuring and integration charges (a) 53
0.5
(8)
—
45
0.39Change in fair value of contingent consideration (b)(10)
(0.1)
—
—
(10)
(0.09)Other charges (c)52
0.4
(13)
—
39
0.34Gains and losses on investments (d)—
—
1
2
(4)
(0.03)Other gains (e)(46)
(0.4)
14
(8)
(41)
(0.36)Amortization expense154
1.4
(39)
—
115
1.01ETB—
—
(18)
—
(18)
(0.16)As adjusted$             1,759
15.9 %
$               (377)
$                   36
$              1,118
$                9.85 
Three Months Ended December 31, 2024
(dollars in millions, except per share data)
Operating income
Operating income as a percentage of net revenues
Income tax expense (f)
Equity in earnings of equity method
investees, net of taxes
Net income  attributable to Quest Diagnostics
Diluted EPSAs reported$                361
13.8 %
$                 (68)
$                     5
$                 222
$                1.95Restructuring and integration charges (a)17
0.6
(5)
—
12
0.11Change in fair value of contingent consideration (b)(8)
(0.2)
—
—
(8)
(0.07)Other charges (c)2
—
—
—
2
0.01Gains and losses on investments (d)—
—
(1)
4
3
0.03Other gains (e)—
—
1
—
(3)
(0.02)Amortization expense37
1.4
(9)
—
28
0.25ETB—
—
(3)
—
(3)
(0.03)As adjusted$                409
15.6 %
$                 (85)
$                     9
$                 253
$                2.23 
Twelve Months Ended December 31, 2024
(dollars in millions, except per share data)
Operating income
Operating income as a percentage of net revenues
Income tax expense (f)
Equity in earnings of equity method investees, net of taxes
Net income  attributable to Quest Diagnostics
Diluted EPSAs reported$             1,346
13.6 %
$               (273)
$                   19
$                 871
$                7.69Restructuring and integration charges (a)62
0.6
(15)
—
47
0.42Change in fair value of contingent consideration (b)2
—
—
—
2
0.02Other charges (c)4
0.1
—
—
3
0.02Gains and losses on investments (d)—
—
(4)
15
11
0.10Other gains (e)—
—
3
—
(9)
(0.08)Amortization expense127
1.3
(32)
—
95
0.84ETB—
—
(9)
—
(9)
(0.08)As adjusted$             1,541
15.6 %
$               (330)
$                   34
$              1,011
$                8.93 

(a)For both the three and twelve months ended December 31, 2025 and 2024, the pre-tax impact represents costs primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business.  The following table summarizes the pre-tax impact of restructuring and integration charges on our consolidated statements of operations:




Three Months Ended December 31,
Twelve Months Ended December 31,
2025
2024
2025
2024
(dollars in millions)Cost of services$              4
$              8
$            12
$            27Selling, general and administrative11
9
40
37Other operating (income) expense, net1
—
1
(2)







Operating income$            16
$            17
$            53
$            62





(b)The pre-tax impact for all periods relates to the change in the fair value of the contingent consideration accrual associated with previous acquisitions.  Such impact is recorded in other operating (income) expense, net in our consolidated statement of operations.





(c)The pre-tax impact for the three and twelve months ended December 31, 2025 primarily includes $7 million of charges to earnings related to legal matters (recorded in selling, general and administrative expenses in our consolidated statement of operations).  The pre-tax impact for the twelve months ended December 31, 2025 also includes an impairment charge of $29 million on certain long-lived assets related to the exit of a business and $15 million of charges to earnings related to legal matters.  Such amounts are recorded in other operating (income) expense, net in our consolidated statement of operations.  The following table summarizes the pre-tax impact of these other items on our consolidated statement of operations:




Three Months Ended December 31,
Twelve Months Ended December 31,
2025
2024
2025
2024
(dollars in millions)Cost of services$            —
$              2
$            —
$              2Selling, general and administrative7
—
7
2Other operating (income) expense, net1
—
45
—Operating income$              8
$              2
$            52
$              4





(d)For all periods presented, the pre-tax impact represents gains and losses associated with changes in the carrying value of our strategic investments, principally recorded in other income, net. 





(e)The twelve months ended December 31, 2025 includes a $46 million pre-tax gain, recorded in other operating (income) expense, net, from a payroll tax credit under the Coronavirus Aid, Relief, and Economic Security Act associated with the retention of employees.  Also, the twelve months ended December 31, 2025 includes a pre-tax gain, recorded in equity in earnings of equity method investees, net of taxes, representing a non-recurring gain related to a lease.  The twelve months ended December 31, 2024 principally includes a non-recurring $8 million pre-tax gain, recorded in other income, net, associated with a foreign exchange forward contract utilized in conjunction with an acquisition.  The following table summarizes the pre-tax impact of these other gains on our consolidated statements of operations:




Three Months Ended December 31,
Twelve Months Ended December 31,
2025
2024
2025
2024
(dollars in millions)Other operating (income) expense, net$             —
$             —
$             46
$             —







Other income, net$             —
$               3
$             —
$             12







Equity in earnings of equity method investees, net of taxes$             —
$             —
$               8
$             —





(f)For restructuring and integration charges, other gains/charges, gains and losses on investments and amortization expense, income tax impacts, where recorded, were primarily calculated using combined statutory income tax rates of 25.5% for both 2025 and 2024.  No income tax impact was recorded on gains/losses associated with the change in the fair value of the contingent consideration accrual associated with previous acquisitions.  The three and twelve months ended December 31, 2025 include $5 million of income tax expense related to the disposal of a business. 



3)For the twelve months ended December 31, 2025,  we repurchased 2.5 million shares of our common stock for $452 million.  As of December 31, 2025, $0.4 billion remained available under our share repurchase authorization.

4)The outlook for adjusted diluted EPS represents management's estimates for the full year 2026 before the impact of special items. Further impacts to earnings related to special items may occur throughout 2026. Additionally, the amount of ETB is dependent upon employee stock option exercises and our stock price, which are difficult to predict. The following table reconciles our 2026 outlook for diluted EPS under GAAP to our outlook for adjusted diluted EPS:


Low
HighDiluted EPS$          9.45
$          9.65Restructuring and integration charges (a)0.07
0.07Amortization expense (b)1.03
1.03Other charges (c)0.11
0.11ETB(0.16)
(0.16)Adjusted diluted EPS$        10.50
$        10.70

(a)Represents estimated pre-tax charges of $12 million primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business.  Income tax benefits were primarily calculated using a combined statutory income tax rate of 25.5%.





(b)Represents estimated pre-tax amortization expenses of $155 million.  Income tax benefits were primarily calculated using a combined statutory income tax rate of 25.5%. 





(c)Principally includes estimated pre-tax net charges of $12 million associated with the estimated change in the fair value of the contingent consideration accrual associated with previous acquisitions.  Such estimate is subject to the risks and uncertainties discussed in the "Forward Looking Statements" section above.  No income tax impacts were recorded on the change associated with the contingent consideration accrual. 



View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-reports-fourth-quarter-and-full-year-2025-financial-results--provides-guidance-for-full-year-2026-increases-quarterly-dividend-7-5-to-0-86-per-share-302683210.htmlSOURCE Quest Diagnostics

Original: Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share

Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase AuthorizationFebruary 10, 2026 6:33 AM
PR Newswire (US)

SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced that the Company's Board of Directors has authorized a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80 per share. The increase is effective with the dividend payable on April 20, 2026 to shareholders of record of Quest Diagnostics common stock on April 6, 2026. With the increase, the annual cash dividend will be $3.44 per share.







Additionally, the Board of Directors has increased the Company's share repurchase authorization by $1 billion. The increased authority is in addition to the approximately $0.4 billion that was available as of December 31, 2025 under the Company's share repurchase program.About Quest DiagnosticsQuest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com



View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-increases-dividend-7-5-to-0-86-per-quarter-marking-15-consecutive-years-of-dividend-increases-announces-1-billion-increase-in-share-repurchase-authorization-302683204.htmlSOURCE Quest Diagnostics

Original: Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization

Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual DiseaseFebruary 2, 2026 8:52 AM
PR Newswire (US)

New test as sensitive as next-generation sequencing, and provides five-day specimen stability to support nationwide testingSECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel blood test that uses advanced flow cytometry methods to assess measurable residual disease (MRD) in patients with the blood cancer myeloma (also called multiple myeloma). Called Quest Flow Cytometry MRD for Myeloma, the new test provides comparable sensitivity as next-generation sequencing methods in detecting residual myeloma*, but at a fraction of the cost, supporting better care and outcomes.







"Our Flow Cytometry MRD for Myeloma test harnesses cutting-edge science and technology to deliver ultrasensitive insights from a noninvasive blood test, thereby improving care and value for patients and the healthcare system," said board-certified oncologist and hematologist Yuri Fesko, M.D., Senior Vice President and Chief Medical Officer, Quest Diagnostics. "This new test merges this elite performance with improved access, given Quest's approximately 7,000 phlebotomy sites across the United States, helping to illuminate a path to better health for more patients."Advancing disease detection for a prevalent blood cancerMyeloma is a cancer of plasma cells, a type of white blood cell, in which dysregulated growth leads to the creation of abnormal antibodies affecting the blood and bones. About 36,000 new cases of myeloma are diagnosed every year in the United States, and nearly 11,000 patients die of the disease annually, according to the American Cancer Society, making it one of the most common types of plasma cell cancers. While incurable, myeloma can often be treated as a chronic condition using chemotherapy and other personalized treatments and guided by MRD monitoring during and after treatment. Physicians typically assess MRD using flow cytometry methods that detect abnormal cells in bone marrow aspirates, a type of biopsy. In recent years, next-generation sequencing has been deployed on both blood and bone marrow aspirate specimens, improving sensitivity tenfold compared to conventional flow cytometry, but at a higher price point.The new test from Quest is unique for using next-generation flow cytometry techniques with a level of detection comparable to next-generation sequencing but on noninvasive blood specimens instead of bone marrow aspirates. In addition, the test can be used in situations where a baseline aspirate sample is not available, unlike NGS methods, which require a pre-treatment baseline sample to provide a reference for ongoing monitoring. The test also features five-day specimen stability, compared to three or fewer days by conventional flow cytometry, supporting access when specimen transport to the lab takes several days."The enthusiastic response received at the recent American Society of Hematology (ASH) Annual Meeting and Exposition upon educating the medical community about the Quest Flow Cytometry MRD for Myeloma test made it clear to me that this assay has the potential to greatly improve the treatment paradigm," said Timothy Looney, PhD, Senior Director, Immuno-Oncology, Quest Diagnostics. "The sensitivity, cost, and sample stability that we can now offer to patients and their care team will help those suffering from this potentially devastating condition."In addition to supporting clinical care, the Quest Flow Cytometry MRD for Myeloma test is expected to have utility as a response monitoring tool in clinical trials. In January 2026, the FDA provided draft guidance on using MRD as a primary endpoint in trials evaluating drug and biological products to treat patients with multiple myeloma to support accelerated approval.Quest is a leading provider of oncology testing services, including the Haystack MRD® test for assessing MRD in solid tumor cancers. This new offering complements Quest's comprehensive portfolio of hematopathology and advanced molecular oncology testing and services aiding care and outcomes for patients with cancer.About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.*Data on File



View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-launches-novel-flow-cytometry-mrd-blood-test-for-myeloma-enabling-ultrasensitive-detection-of-residual-disease-302675315.htmlSOURCE Quest Diagnostics

Original: Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease

DGX new 52=week high

DGX 10Q due JULY23

DGX on the list during this selloff

DGX in Seeking Alpha

https://seekingalpha.com/article/4481363-quest-diagnostics-last-stock-standing-on-my-quality-plus-value-screen?mailingid=26477789&messageid=investing_ideas&serial=26477789.58155&utm_campaign=Stock%2BIdeas%2BRecurring%2B%2B2022-01-25&utm_content=investing_ideas_control&utm_medium=email&utm_source=seeking_alpha&utm_term=Investing%2BIdeas

JUST IN: $DGX 3 Back-to-School Stocks to Buy Right Now

School's back in session, and with the coronavirus pandemic still around, it's going to be a challenging year for teachers and students. For investors, however, it's an opportunity to invest strategically in companies that are likely to see demand for their products and services rise as the...

Find out more DGX - 3 Back-to-School Stocks to Buy Right Now

$DGX | #QuestDiagnostics on Breakout Alert


alert set for break above $125.
Will look for confirmation with volume on 3-5min closes.
Multiple Fib expansion and extension targets provided with $130 & $137
levels as levels of confluence
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.

News: $DGX FDA Authorizes Quest Diagnostics COVID-19 Diagnostic Testing for Specimen Pooling for Emergency Use

SECAUCUS, N.J. , July 18, 2020 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to use specimen pooling ...

Read the whole news DGX - FDA Authorizes Quest Diagnostics COVID-19 Diagnostic Testing for Specimen Pooling for Emergency Use

$DGX https://247wallst.com/healthcare-business/2020/05/11/covid-19-testing-continues-to-lift-aytu-bioscience-stock/

Quest Diagnostics shares are trading higher after Morgan Stanley maintained an Overweight rating and raised its price target from $139 to $146.

Ready to break new highs!

Is quest using the same antibody test that tomdf is using? Both news came out today. Is it arrayit finger stick

DGX$$$$$ $120 TARGET PRICE

tavito DGX$$$$ back over $100 today WOOHOOOOOOOOOOO GOOD LUCK $120 Target price this week

I’m with you!!

DGX$$$$ BUYING any dip here $$$$$

DGX$$$$$ helping to fight against Chinese biological warfare attack. Let's drop a nuclear bomb on them before they kill us they hate us. President should stop Chinese from buying our real estate here. Pretty soon America will be China. They're taking the money they stole from USA and buying our real estate with it. We're fighting to silent Wars against China them buying our real estate and then putting deadly germs here. And don't forget the fish that they are putting in our Waters and the bugs that they were letting lose here that is killing our plants and trees. These motherfckers live off of bugs and the species of fish that they are putting in our Waters they eat. Chinese planned on coming to live here in the United States killing us off. They have no other choice they have too many people in their country they cannot breathe.

DGX$$$$$ Millionaires play WOOHOOOOOOOOOOOO maybe big buy out here

DGX$$$BIG GREEN MOVE COMING WOOHOO$$$ $130 Target price this week

WOOHOOOOOOOO DGX$$$$ $200 TARGET PRICE

A friend asked me to do analysis on this stock. I am a technician by trade. I thought I'd put up my two cents...…

Quest is like many of the larger companies right now - most insiders are distributing. The Fed has everything screwed up. Insiders are getting out while there is something to get out of.

Monthly chart was a solid long March of 2019. After seeing insider action I quit researching Quest. That said, the 2008/09 jacking was not severe and the coming jacking may be similar, however, this time will likely be far more severe.

News: $DGX Quest Diagnostics Reports First Quarter 2019 Financial Results

SECAUCUS, N.J. , April 23, 2019 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the first quarter ended March 31, 2019 . "We're off to a good start in 2019, wi...

Find out more https://marketwirenews.com/news-releases/quest-diagnostics-reports-first-quarter-2019-financial-results-8041322.html

I'm sitting in a quest diagnostics right now for the first time. First thing I notice is no secretary to check in, just a computer. I'm thinking this company is making money hand over fist and are cut throut. So I check the stock and see it's down about 20% since October. How come?

News: $DGX Quest Diagnostics Named One of 2019 "World's Most Admired Companies" by Fortune Magazine for Fourth Consecutive Year

SECAUCUS, N.J. , Jan. 22, 2019 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been selected as one of FORTUNE's World's Most Admired Companies in 2019 for the fourth consecutive yea...

Find out more https://marketwirenews.com/news-releases/quest-diagnostics-named-one-of-2019-world-s-most-admired-companies-by-fortune-magazine-for-fourth-consecutive-year-7429856.html

In Quest $DGX Of A Trade Level

This morning, leading diagnostic testing and information services company to the healthcare industry, Quest Diagnostics Inc (NYSE:DGX), is falling sharply after lowering guidance. Quest Diagnostics Inc (NYSE:DGX) stock is dropping by 9.32 percent to $87.87 a share. The stock is breaking down from a bearish daily chart base and this indicates lower prices ahead. The next key support level that should be watched closely will be the $80.00 area. This is where the stock broke out of a monthly chart bullish base in 2017. Often, when stocks retest prior break-out levels it will be defended by the institutional money crowd.





Nicholas Santiago
InTheMoneyStocks

Waiting for another DIP 100<

$111.50 New 52WK High

hats off to QUEST!

She needs to cool down.

Good money made and another divi soon!

10% expecting market pullback EOW

Div Paid

THX

Exec Orders Will be challenged

if he proceeds. 10 Billion dollar company should be trading in the $150.00 range!

In @ 92.58

10% GAINS COMING!

BUY BUY BUY

Totally agree. Value added IMHO.

Cashflow models imply Quest Diagnostics Inc $DGX has 7% Upside before earnings Thursday:

Fair Value Analysis

Even though it's trading at an all time high I'm taking a starter position with 10 shares with the idea of dollar averaging.

DGX needs SGBY IMHO